Layoffs and resignations in pharmaceutical enterprises are on the rise, which leads to a battle for professional talents

[pharmaceutical network market analysis] in recent years, the trend of layoffs and resignations in the pharmaceutical industry is one after another According to the statistics of the insiders, since 2018, the total number of layoffs of famous multinational pharmaceutical companies such as Novartis, Pfizer, Sanofi and GSK has reached nearly 20000 Recently, Novartis also announced that it will cut 320 jobs in Ireland, involving 240 employees in the active pharmaceutical ingredients (API) factory and 80 employees in the Global Services Department In addition, in 2019, under the influence of consistency evaluation, volume purchase and other policies, Chinese pharmaceutical enterprises are also changing from generic drugs to generic drugs and innovative drugs, and personnel changes, especially talent changes, have become the general trend According to incomplete statistics, from January 2019 to October, at least 90 executives resigned, including Novartis, Merck, Mercedes, Taiji group, Li Zhu group, Tianmu pharmaceutical, essence pharmaceutical and other well-known pharmaceutical companies at home and abroad What is the reason why pharmaceutical companies frequently make layoffs and personnel adjustments? The industry believes that pharmaceutical companies, especially multinational pharmaceutical companies, are generally affected by the pharmaceutical environment and policies After all, their good days of "lying down to make money" have passed For example, Novartis said in response to the media that its layoffs will be completed by the middle of 2022, which will help streamline the organizational structure and focus resources on innovative research and development According to foreign media, MSD announced that it would cut about 500 jobs in many states of the United States from January 3, 2020, mainly involving the sales team It is reported that the purpose of MSD's downsizing is also to better focus on innovation and R & D Alkermes, an Irish biopharmaceutical company, recently announced 160 job cuts, which it said were aimed at restructuring and preventing losses Data show that Alkermes reported a net loss of $53 million in its third quarter earnings report, up $34 million from the same period last year The restructuring may help the company save hundreds of millions of dollars in costs Under the condition of changing medical pattern, domestic pharmaceutical enterprises also need to transform and upgrade Some insiders said that driven by the policies of consistency evaluation, medical insurance fee control and volume purchase, the generic pharmaceutical industry is facing a cold winter It is conservatively estimated that at least one third of the domestic pharmaceutical enterprises will face bankruptcy, and the remaining pharmaceutical enterprises need to accept more rigorous tests In recent years, many well-known pharmaceutical enterprises, such as Fosun Pharmaceutical, have chosen to set up R & D institutions overseas The purpose is to attract overseas local talents, so that they can also provide R & D support for pharmaceutical enterprises without leaving the country And according to people from investment institutions, as local biological enterprises have set up branches overseas, international competition for professional talents has begun to rise For example, before and after the IPO of Baiji Shenzhou on Nasdaq, its core team joined three doctors who had worked for Genetech in the United States They were Amy Peterson, medical officer of tumor immunology, Jane Huang, medical officer of Hematology, and Eric Hedrick, clinical medical consultant Among them, Eric Hedrick also persuaded other colleagues at Genetech to come to Baiji, expanding the number of employees in the United States to more than 400 In addition, the "flow back" of Chinese talents from overseas pharmaceutical companies is continuing For example, in March this year, Li Zhengqing, former global vice president and general manager of China R & D center, became Geli biomedical officer and President of R & D in Greater China; on March 4, Harbin Pharmaceutical Co., Ltd decided to appoint Xu Haiying, President of Novartis group in China, as general manager of the company, etc In general, it is inevitable for the change of medical pattern students Pharmaceutical enterprises need to adjust the talent structure according to the market development trend and their own needs At the same time, under the background that innovative drugs and generic drugs become the new research and development direction, they have many high-level personnel such as overseas study background and management experience of multinational enterprises or become the main force of the development of domestic pharmaceutical enterprises.